Capricor Therapeutics (CAPR) Stock Plunges -81% After FDA Raises Questions on Deramiocel Data

Key Takeaways

• Capricor Therapeutics (CAPR) shares plummeted approximately 81% over the past 30 days, falling from $22.43 on July 6 to $4.17 by August 4, 2026.
• The collapse was triggered by an FDA briefing document released July 27 that challenged the statistical validity of Deramiocel's Phase 3 HOPE-3 trial results, contradicting Capricor's earlier positive characterization.
• An FDA Advisory Committee subsequently voted 9-to-3 against finding sufficient evidence supporting Deramiocel's effectiveness for treating cardiomyopathy in Duchenne muscular dystrophy (DMD).
• Multiple securities fraud class action lawsuits have been filed, alleging the company misled investors about the integrity of its clinical trial data and statistical analysis plan.
• The FDA's final PDUFA target action date remains August 22, 2026, representing a critical binary catalyst for the stock.
• Wall Street analysts have issued sharp downgrades, with multiple firms slashing price targets from the $38–$63 range down to single digits.

Capricor Therapeutics (CAPR) Company Overview and Market Position

Capricor Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California, focused on developing cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel (CAP-1002), is an allogeneic cardiosphere-derived cell therapy currently under FDA review for the treatment of Duchenne muscular dystrophy (DMD), a severe genetic disorder causing progressive muscle degeneration and premature death, primarily affecting young males. Deramiocel has received Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT), and Rare Pediatric Disease designations from the FDA. Beyond Deramiocel, Capricor also advances its proprietary StealthX™ exosome platform for targeted delivery of oligonucleotides, proteins, and small molecules. With no approved products and no revenue, the company's entire investment thesis and market valuation hinge on a favorable regulatory outcome for Deramiocel.

CAPR Stock Price Performance: Last 30 Days vs. Quarter

CAPR shares have experienced one of the most dramatic biotech selloffs of 2026. Over the last 30 days, the stock collapsed from a closing price of $22.43 on July 6 to $4.17 on August 4, 2026 — an approximate 81% decline. The majority of that drop occurred in two violent trading sessions: a 64% single-day plunge on July 27 following the FDA's release of its briefing document, followed by an additional 36% decline on July 30 after the Advisory Committee vote. Over the broader quarter, the stock has fared even worse — down approximately 88% since early May 2026, when shares traded around $34. The collapse has erased well over $1 billion in market capitalization, reducing the company's valuation to approximately $241 million. To compare sector peers during similar events, I also checked this using Tickeron’s AI Screener.

What Drove CAPR Stock Price in the Last 30 Days

The principal catalyst for CAPR's collapse was the July 27 release of the FDA's briefing document ahead of the July 29 Cellular, Tissue, and Gene Therapies Advisory Committee meeting. The FDA document stated that the HOPE-3 Phase 3 trial "did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months." This directly contradicted Capricor's December 2025 announcement of "positive topline results" and claims of "strong and definitive evidence" that Deramiocel could meaningfully improve DMD outcomes. Furthermore, the FDA raised concerns about post-hoc changes to the statistical analysis plan (SAP), noting that at least two additional SAP versions were generated after the pre-specified plan, including modifications to endpoint definitions, analytical methods, and data-imputation strategies.

Capricor responded that the FDA had relied on an "unsigned, incomplete internal draft" — SAP version 1.1 — rather than the final SAP version 3.0 that governed reported results. However, the market reaction was swift and unforgiving. On July 30, the Advisory Committee voted 9-to-3 against finding sufficient evidence to support Deramiocel's effectiveness for DMD-associated cardiomyopathy. The vote, while non-binding and addressing a narrower indication than Capricor had proposed, severely undermined confidence in the Biologics License Application (BLA). Multiple analyst downgrades followed, with B. Riley, Roth Capital, and others cutting ratings to Neutral and slashing price targets from as high as $63 to between $7 and $10. Several law firms also launched securities fraud investigations and class action lawsuits on behalf of shareholders.

What Drove CAPR Stock Performance Over the Last Quarter

The quarterly decline reflects a broader unraveling of the Deramiocel investment thesis that had driven CAPR shares above $34 in early May. Throughout the second quarter, bullish sentiment was sustained by Capricor's repeated assertions of statistically significant HOPE-3 results, analyst price targets averaging above $50, and optimism ahead of the July 29 AdComm. The company also entered into an FDA-contingent headquarters lease for approximately 171,000 square feet in San Diego in early July, signaling confidence in approval. However, removal from several Russell indexes in late June and growing short-seller scrutiny foreshadowed vulnerability. The AdComm's negative vote not only devastated near-term approval prospects but also called into question the integrity of Capricor's data disclosures since December 2025, opening the door to significant legal exposure and regulatory uncertainty heading into the August 22 PDUFA date.

CAPR Stock Forecast Drivers: What Investors Should Watch Next

The most consequential event for CAPR is the FDA's final decision on the Deramiocel BLA by the August 22, 2026 PDUFA target action date. While the negative AdComm vote is non-binding, it historically carries significant weight with FDA review teams and substantially reduces the probability of approval. Investors should also monitor Capricor's upcoming quarterly earnings report, anticipated around August 11, for updates on its cash position — the company reported $278.6 million as of Q1 2026, projected to fund operations through late 2027. The mounting securities class action lawsuits represent another material risk, as litigation costs and potential settlement liabilities could strain resources regardless of the FDA outcome. Should Deramiocel be rejected, Capricor may need to reassess its corporate strategy, pipeline priorities, and capital allocation given that Deramiocel represents its only late-stage asset. On the upside, any unexpected positive regulatory development or constructive FDA communication could trigger a sharp recovery in the heavily shorted stock. From what I see, this remains a high-stakes binary event worth monitoring closely.

Navigating Volatility with Data-Driven Tools

In volatile market environments like the one surrounding CAPR, I often look at systematic approaches to stay objective. Tickeron’s Trending AI Robots page features a curated selection of AI-powered trading bots designed to analyze thousands of stocks and ETFs across diverse strategies and timeframes. The bots employ methodologies from swing trading and trend following to momentum and breakout strategies, allowing exploration of approaches matched to different risk profiles.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume